Compare USGO & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USGO | PYXS |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | 10 | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.3M | 172.2M |
| IPO Year | N/A | 2021 |
| Metric | USGO | PYXS |
|---|---|---|
| Price | $10.58 | $1.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $30.75 | $7.00 |
| AVG Volume (30 Days) | 51.0K | ★ 650.1K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,858,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7,043.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.42 | $0.97 |
| 52 Week High | $17.98 | $5.55 |
| Indicator | USGO | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 33.74 | 43.73 |
| Support Level | $10.22 | $1.23 |
| Resistance Level | $11.20 | $2.27 |
| Average True Range (ATR) | 0.59 | 0.30 |
| MACD | -0.33 | -0.08 |
| Stochastic Oscillator | 16.19 | 4.62 |
US Goldmining Inc is a mineral exploration company with a focus on the exploration and development of a project located in Alaska, USA. The company's primary asset is the 100%-owned Whistler exploration property located in Alaska, USA. It operates and reports in one segment, which focuses on the exploration and development of mineral properties.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.